L1CAM and non-small cell lung carcinoma: Although the two cohorts (TCGA and ALTER0303) there may be differences in the population profile, but, here we found that low serum levels of KLK5 and L1CAM at baseline are favorable biomarkers for anlotinib-responsive stratification in NSCLC patients (ALTER0303 cohort) at 3rd line.